secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2024-02-16T23:59:59+00:00
Accession:  0001714899-24-000065
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali partner Sanofi reports Phase 2 ALS trial miss for RIPK1 inhibitor DNL788
-------------------------------------------------------------------------------

- Phase 2 HIMALAYA study of SAR443820/DNL788 in ALS did not meet primary endpoint (ALSFRS-R).
- Sanofi will present detailed efficacy and safety results at a future scientific forum.
- DNL788 is an oral brain-penetrant RIPK1 inhibitor co-developed by Sanofi and Denali.
- Sanofi will continue the K2 Phase 2 study of DNL788 in multiple sclerosis.
- No financial terms disclosed; pipeline setback for Denali's key partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000065/0001714899-24-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000065/dnli-20240216.htm
  HTML page:      https://secwatch.observer/filing/0001714899-24-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer